File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term follow-up in a randomised controlled trial of recombinant α2-interferon in Chinese patients with chronic hepatitis B infection

TitleLong-term follow-up in a randomised controlled trial of recombinant α2-interferon in Chinese patients with chronic hepatitis B infection
Authors
Issue Date1988
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lancet
Citation
Lancet, 1988, v. 2 n. 8606, p. 298-302 How to Cite?
Abstract72 Chinese patients who had been positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) for more than six months with stable serum hepatitis B virus DNA were randomised to receive recombinant α2-interferon at doses of 2.5, 5, or 10 x 106 U/m2 intramuscularly thrice weekly for 12-24 weeks, or no treatment. 6 (11%) of 54 treated and 1 (6%) of 18 control patients became HBeAg-negative at the end of therapy or after 24 weeks of follow-up. 9 (17%) of treated but none of the control patients became HBeAg-negative between completion of therapy and 12 months. Reactivation of HBV replication subsequently occurred in 7 (13%) of the treated patients and in 1 control. Thus, sustained clearance of HBeAg was achieved only in 8 (15%) of treated patients at 12 months. Between 12 and 24 months 3 (9%) of treated patients and 1 control became negative for HBeAg. None of the patients became HBsAg-negative. α2-interferon in the dose regimen used has little long-term effect in the suppression of HBV replication in Chinese patients with chronic HBV infection.
Persistent Identifierhttp://hdl.handle.net/10722/161747
ISSN
2015 Impact Factor: 44.002
2015 SCImago Journal Rankings: 14.638
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLok, ASFen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorLeung, EKYen_US
dc.date.accessioned2012-09-05T05:14:38Z-
dc.date.available2012-09-05T05:14:38Z-
dc.date.issued1988en_US
dc.identifier.citationLancet, 1988, v. 2 n. 8606, p. 298-302en_US
dc.identifier.issn0140-6736en_US
dc.identifier.urihttp://hdl.handle.net/10722/161747-
dc.description.abstract72 Chinese patients who had been positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) for more than six months with stable serum hepatitis B virus DNA were randomised to receive recombinant α2-interferon at doses of 2.5, 5, or 10 x 106 U/m2 intramuscularly thrice weekly for 12-24 weeks, or no treatment. 6 (11%) of 54 treated and 1 (6%) of 18 control patients became HBeAg-negative at the end of therapy or after 24 weeks of follow-up. 9 (17%) of treated but none of the control patients became HBeAg-negative between completion of therapy and 12 months. Reactivation of HBV replication subsequently occurred in 7 (13%) of the treated patients and in 1 control. Thus, sustained clearance of HBeAg was achieved only in 8 (15%) of treated patients at 12 months. Between 12 and 24 months 3 (9%) of treated patients and 1 control became negative for HBeAg. None of the patients became HBsAg-negative. α2-interferon in the dose regimen used has little long-term effect in the suppression of HBV replication in Chinese patients with chronic HBV infection.en_US
dc.languageengen_US
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/lanceten_US
dc.relation.ispartofLanceten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAsian Continental Ancestry Groupen_US
dc.subject.meshChinaen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHepatitis B - Drug Therapyen_US
dc.subject.meshHepatitis B Virus - Physiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon Type I - Adverse Effects - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshVirus Replicationen_US
dc.titleLong-term follow-up in a randomised controlled trial of recombinant α2-interferon in Chinese patients with chronic hepatitis B infectionen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2899719-
dc.identifier.scopuseid_2-s2.0-0023759015en_US
dc.identifier.volume2en_US
dc.identifier.issue8606en_US
dc.identifier.spage298en_US
dc.identifier.epage302en_US
dc.identifier.isiWOS:A1988P544900002-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridLeung, EKY=25224640000en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats